The present invention relates to danazol or a pharmaceutically-acceptable salt of danazol for use in inhibiting vascular hyperpermeability, wherein the danazol or the pharmaceutically-acceptable salt of danazol is administered orally in a daily dose of 10 mg/day to about 90 mg/day or topically or locally at a concentration from 0.0001 µM to 5 µM.